An ideal way to keep informed of the dealmaking activity of 50 of the top pharmaceutical companies.
Partneringdesk™ Deals Briefings provide a comprehensive summary of the deals and alliances announced by 50 of the top pharmaceutical and biotechnology companies and subsidiaries, each covering the period January 2001 to March 2006.Buying Partneringdesk Deals Briefings
The reports include a brief company profile, a financial data and deals overview, and a detailed listing of the company’s deals and alliances.
Information breakdown for every deal entry includes:
- Date of announcement
- Partners
- Deal type
- Industrial sector
- Therapy sector
- Stage of development (where disclosed)
- Deal exclusivity (where disclosed)
- Total deals value (where disclosed)
- Financials (where disclosed)
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies.
Other selected research from the 'Business Development' category:
Pricing and Reimbursement Strategies for Diagnostics: Overcoming reimbursement issues and navigating the regulatory environment
The reimbursement for diagnostics is the key requirement for both the diagnostic providers and the payers because while 5-7% of the hospital cost is incurred on diagnostics, they are used... Learn More
Legal aspects of outsourcing contracts in the pharmaceutical industry: A practical guide
This comprehensive report covers the contractual features of the outsourcing process from start to finish. Whatever your area of expertise, this report includes information on the legal aspects of outsourcing services at all stages of product development, manufacturing and exploitation, including preclinical and clinical research, manufacture, logistics and sales. Learn More
Other selected research from the 'Companies' category:
ACADIA Pharmaceuticals Inc.:Premium Company Profile
PharmaVitae 2004: Shire Pharmaceuticals US & Global Analysis
This analysis examines the market position and future outlook for Shire. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information Learn More